University of Wollongong Report issue

Government Phase 1

Organization Overview

First Clinical Trial
2017
NCT03150927
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

University of Wollongong

Active Ingredients

Drugs in Phase 1 Trials (1)

streptococcus pyogenes (1 trial)

Drugs in Other Trials (1)

autologous microbiome (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 1)

Communicable Diseases (Phase 1)

Gram-Positive Bacterial Infections (Phase 1)

Hemolysis (Phase 1)

Infections (Phase 1)

Pharyngitis (Phase 1)

Streptococcal Infections (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2